Tamsulosin Hydrochloride Capsule
Product Images NDC 71205-688

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 71205-688). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours following a single 0.4 mg oral dose under fasted and fed conditions in 8 subjects. The plasma concentration (ng/mL) is plotted on the vertical axis and time (hours) on the horizontal axis, with separate curves for fasted and fed states.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change over treatment duration weeks. It compares three treatments: 0.8 mg, 0.4 mg, and placebo, with mean change on the y-axis and treatment duration (weeks) on the x-axis. The graph includes sample sizes for each time point and indicates greater symptom score reduction with 0.8 mg and 0.4 mg doses compared to placebo over 13 weeks.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2'. It shows mean symptom score changes over 13 weeks of treatment for Tamsulosin Hydrochloride at 0.4 mg and 0.8 mg doses, and placebo groups. The x-axis is Duration of Treatment (weeks), and the y-axis is Mean Change from baseline. Three distinct lines represent 0.8 mg, 0.4 mg, and placebo treatments with decreasing symptom scores over time.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1', showing mean change in flow rate over treatment duration in weeks. Three treatment groups are displayed: 0.8 mg, 0.4 mg, and placebo. The graph depicts changes from baseline (B) to the last observation collected (LOCF) with sample sizes noted at various weeks.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

Line graph showing mean increase in peak urine flow rate (mL/sec) over duration of treatment in weeks from a clinical study. The graph compares three treatments: 0.8 mg, 0.4 mg doses, and placebo. Mean change increases rapidly initially for active treatments, with 0.8 mg showing highest increase, stabilizing over 13 weeks, while placebo shows minimal increase.*

FDA Label Image

71205-688-14 (Tamsulosin Fig6)

Tamsulosin Hydrochloride 0.4 mg capsules label from Proficient Rx LP. The label states each capsule contains 0.4 mg Tamsulosin hydrochloride USP. The capsules are described as olive green opaque/orange opaque hard gelatin size '0' imprinted with 'D' on the cap and '53' on the body in black edible ink filled with white to off-white beadlets. The package contains 14 capsules distributed by Rising Health, LLC, made in India.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride showing its molecular composition including aromatic rings, functional groups, and the hydrochloride salt component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.